Beauty sales at Sanofi decline 2%

April 1995
WWD: Women's Wear Daily;4/14/1995, Vol. 169 Issue 72, p9
Trade Publication
Reports on the decline in sales of Sanofi SA's beauty products and fragrances during the first quarter of 1995.


Related Articles

  • Sanofi: Time not right to sell off beauty unit.  // WWD: Women's Wear Daily;9/8/1997, Vol. 174 Issue 48, p4 

    Focuses on pharmaceuticals and beauty products company, Sanofi's executive vice president for administration and finance, Jean-Paul Leon's issuance of a statement to clarify French business newspapers report that the company is planning to sell off its beauty division. Overview on Sanofi's...

  • Third alternative. Horton, Kathleen // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p92 

    Reports on Sanofi SA's acquisition of the rights to market Hyalgan (hyaluronate) in the United States.

  • Sanofi operating net drops 35% in fragrance, beauty areas in '94.  // WWD: Women's Wear Daily;3/16/1995, Vol. 169 Issue 51, p24 

    Reports on the financial performance of Sanofi in 1994. Operating profits from fragrance and beauty products; Sales; Earnings.

  • Sanofi beauty sales off 4.3% in 4th quarter.  // WWD: Women's Wear Daily;2/11/1997, Vol. 173 Issue 28, p9 

    Reports on the decline in Sanofi SA beauty sector's sales in the fourth quarter of 1996. Expected increase in earnings as compared to year-ago results; Growth in Yves Saint Laurent's Opium lines for men and women; Increase in total company sales.

  • Back in black.  // WWD: Women's Wear Daily;9/1/1995, Vol. 170 Issue 43, p5 

    Reports on Sanofi SA's breakeven in operating profit for its perfumes and beauty division in the first half of 1995. Improvement in earnings due to a restructuring of its distribution and sale of unprofitable brands such as Stendhal, Perry Ellis and Geoffrey Beene.

  • Sanofi sales up 3.6 percent.  // WWD: Women's Wear Daily;7/22/1994, Vol. 168 Issue 15, p7 

    Reports that Sanofi's sales for its fragrance and beauty division reached $369.4 million for the first six months of 1994. Comparison with 1993 sales; Brand gainers.

  • Sanofi sales grow 10% in first 9 months of '97.  // WWD: Women's Wear Daily;11/5/1997, Vol. 174 Issue 87, p18 

    Reports on sales growth of French pharmaceuticals and beauty giant Sanofi for the first nine months of 1997.

  • French drug maker Sanofi has begun construction on its new Algerian facility.  // African Business News;10/2/2013, p8 

    The article reports that construction on the new Algerian facility of French drug maker Sanofi has been started.

  • Dronedarone Tablets (Multaq®). Elliott, William T.; Chan, James // Internal Medicine Alert;9/15/2009, Vol. 31 Issue 17, p133 

    The article offers information on the nature, dosage, potential physiological benefits and hazards, and clinical implications of the Dronedarone drug tablets, marketed as Multaq® by Sanofi-Aventis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics